<DOC>
	<DOCNO>NCT02323607</DOCNO>
	<brief_summary>This phase I trial study side effect best dose pacritinib give together chemotherapy treat patient acute myeloid leukemia abnormal change ( mutation ) fms-related tyrosine kinase 3 ( FLT3 ) gene . Pacritinib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine , daunorubicin hydrochloride , decitabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving pacritinib chemotherapy may better treatment acute myeloid leukemia FLT3 mutation .</brief_summary>
	<brief_title>Pacritinib Chemotherapy Treating Patients With Acute Myeloid Leukemia FLT3 Mutations</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety tolerability pacritinib combination 7+3 decitabine ( respective cohort independent ) patient newly diagnose relapsed/refractory acute myeloid leukemia ( AML ) FLT3 mutation . II . To define specific toxicity , maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) combination . III . To determine recommended phase 2 dose ( RP2D ) combination . SECONDARY OBJECTIVES : I . To determine rate duration complete remission ( CR ) +/- hematologic recovery pacritinib 7+3 decitabine AML . II . To determine overall response rate ( ORR ) disease free survival 1 year . TERTIARY OBJECTIVES : I . To conduct pharmacokinetic study pacritinib combination chemotherapy . II . To determine impact pacritinib inhibition Janus kinase 2 ( JAK2 ) , FLT3 , AXL receptor tyrosine kinase ( AXL ) , signal transducer activator transcription 5A ( STAT5 ) , spleen tyrosine kinase ( Syk ) . III . To examine exosome , cytokine , chemokine change FLT3 down-stream inhibition pacritinib . IV . To examine resistance pattern associate treatment pacritinib . V. To examine baseline cytogenetic , GTP bind protein overexpressed skeletal muscle ( GEM ) signature , long non-coding ( Lnc ) ribonucleic acid ( RNA ) signature mutational status AML tumor cell well identify subset patient high likelihood respond therapy . OUTLINE : This dose-escalation study pacritinib . Patients assign 1 2 treatment arm . COHORT A : INDUCTION : Patients receive pacritinib orally ( PO ) day 1-21 , cytarabine intravenously ( IV ) every 24 hour day 5-11 , daunorubicin hydrochloride IV every 24 hour day 5-7 . Treatment repeat every 28 day 1-2 course absence disease progression unacceptable toxicity . COHORT B : INDUCTION : Patients receive pacritinib PO day 1-21 decitabine IV every 24 hour day 5-14 . Treatment repeat every 28 day 2-4 course absence disease progression unacceptable toxicity . MAINTENANCE : Patients achieve CR proceed transplant evaluation ( appropriate ) . Transplant-ineligible patient receive maintenance course pacritinib PO day 1-21 decitabine IV 1 hour daily day 1-5 . Maintenance course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients AML presence FLT3 mutation Patients secondary AML therapy related disease ( tAML ) eligible If patient comorbid medical illness , life expectancy attribute must great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Total bilirubin &lt; 2.0mg/dL unless due Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal Creatinine ( Cr ) clearance &gt; 50 mL/min CockcroftGault calculation New York Heart Association ( NYHA ) congestive heart failure ( CHF ) class II good Cardiac ejection fraction &gt; = 50 % Arm A , &gt; = 40 % Arm B Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential ; acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal ; male female patient , effective method contraception must use throughout study three month follow last dose Ability understand willingness sign write informed consent document Human immunodeficiency virus ( HIV ) infection without history acquire immune deficiency syndrome ( AIDS ) sufficiently high cluster differentiation ( CD ) 4 cell ( &gt; 400/mm^3 ) low HIV viral load ( &lt; 30,000 copies/ml plasma ) require antiHIV therapy eligible Patients corebinding factor AML ( inv [ 16 ] , [ 8 ; 21 ] ) ( 15 ; 17 ) Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study ; treatment hydroxyurea permit cycle 1 maintain white blood cell ( WBC ) &lt; 40,000/uL Patients receive investigational agent patient receive investigational agent within 14 day enrollment Patients active central nervous system ( CNS ) malignancy Major surgery within 2 week day 1 Uncontrolled active infection ; patient infection require parenteral antibiotic eligible infection control Patients significantly diseased obstruct gastrointestinal tract Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) , unstable angina pectoris , myocardial infarction within 6 month prior enrollment , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiogram ( ECG ) abnormality screen document investigator medically relevant Patients serious medical psychiatric illness likely interfere participation clinical study Pregnant woman woman breastfeed exclude study ; confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilized woman Patients advanced malignant solid tumor Patients able swallow capsule tablet Patients baseline correct QT ( QTc ) &gt; 500 m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>